文献速递精神分裂症与精神病性障碍

精神分裂症患者辅助精神药物治疗的比较有效性

Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia.
PubMed 文献 · JAMA Psychiatry · 2019-01-01

该研究基于美国全国医疗补助数据,纳入81 921例稳定接受单一抗精神病药治疗的成人精神分裂症门诊患者,比较启动抗抑郁药、苯二氮䓬类、心境稳定剂或另一种抗精神病药后365天内的精神科住院、急诊就诊和全因死亡风险。与启动另一种抗精神病药相比,启动抗抑郁药与较低的精神科住院和急诊风险相关,而启动苯二氮䓬类与较高的精神科住院和急诊风险相关,启动心境稳定剂与较高的死亡风险相关。

要点

  • 与换用另一种抗精神病药相比,加用抗抑郁药与较低的精神科住院和急诊风险相关。
  • 加用苯二氮䓬类与较高的精神科住院和急诊风险相关,临床应谨慎。
  • 加用心境稳定剂与较高的死亡风险相关,需进一步研究。

核心结论

  • 在精神分裂症治疗中,与启动另一种抗精神病药相比,启动辅助抗抑郁药与较低的精神科住院和急诊风险相关。
  • 启动苯二氮䓬类和心境稳定剂与较差结局相关,提示临床应谨慎并需进一步研究。

研究设计与样本

  • 比较有效性研究,使用美国全国医疗补助数据(2001年1月1日至2010年12月31日)。
  • 纳入81 921例18-64岁稳定接受单一抗精神病药治疗的成人精神分裂症门诊患者。
  • 采用倾向评分加权Cox比例风险模型,按意向治疗原则比较365天内结局。

主要发现

  • 与启动另一种抗精神病药相比,启动抗抑郁药的精神科住院风险较低(HR,0.84;95% CI,0.80-0.88)。
  • 启动苯二氮䓬类的精神科住院风险较高(HR,1.08;95% CI,1.02-1.15)。
  • 启动心境稳定剂的精神科住院风险无显著差异(HR,0.98;95% CI,0.94-1.03)。
  • 精神科急诊就诊呈现相似模式:抗抑郁药HR,0.92(95% CI,0.88-0.96);苯二氮䓬类HR,1.12(95% CI,1.07-1.19);心境稳定剂HR,0.99(95% CI,0.94-1.04)。
  • 启动心境稳定剂与死亡风险增加相关(HR,1.31;95% CI,1.04-1.66)。

临床怎么用

  • 对于稳定接受单一抗精神病药治疗的精神分裂症患者,加用抗抑郁药可能降低精神科住院和急诊风险。
  • 加用苯二氮䓬类或心境稳定剂前应权衡潜在风险,尤其是心境稳定剂与死亡风险相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: People with schizophrenia are commonly treated with psychotropic medications in addition to antipsychotics, but there is little evidence about the comparative effectiveness of these adjunctive treatment strategies. OBJECTIVE: To study the comparative real-world effectiveness of adjunctive psychotropic treatments for patients with schizophrenia. DESIGN, SETTING, AND PARTICIPANTS: This comparative effectiveness study used US national Medicaid data from January 1, 2001, to December 31, 2010, to examine the outcomes of initiating treatment with an antidepressant, a benzodiazepine, a mood stabilizer, or another antipsychotic among adult outpatients (aged 18-64 years) diagnosed with schizophrenia who were stably treated with a single antipsychotic. Data analysis was performed from January 1, 2017, to June 30, 2018. Multinomial logistic regression models were used to estimate propensity scores to balance covariates across the 4 medication groups. Weighted Cox proportional hazards regression models were used to compare treatment outcomes during 365 days on an intention-to-treat basis. MAIN OUTCOMES AND MEASURES: Risk of hospitalization for a mental disorder (primary), emergency department (ED) visits for a mental disorder, and all-cause mortality. RESULTS: The study cohort included 81 921 adult outpatients diagnosed with schizophrenia (mean [SD] age, 40.7 [12.4] years; 37 515 women [45.8%]) who were stably treated with a single antipsychotic and then initiated use of an antidepressant (n = 31 117), a benzodiazepine (n = 11 941), a mood stabilizer (n = 12 849), or another antipsychotic (n = 26 014) (reference treatment). Compared with initiating use of another antipsychotic, initiating use of an antidepressant was associated with a lower risk (hazard ratio [HR], 0.84; 95% CI, 0.80-0.88) of psychiatric hospitalization, whereas initiating use of a benzodiazepine was associated with a higher risk (HR, 1.08; 95% CI, 1.02-1.15); the risk associated with initiating use of a mood stabilizer (HR, 0.98; 95% CI, 0.94-1.03) was not significantly different from initiating use of another antipsychotic. A similar pattern of associations was observed in psychiatric ED visits for initiating use of an antidepressant (HR, 0.92; 95% CI, 0.88-0.96), a benzodiazepine (HR, 1.12; 95% CI, 1.07-1.19), and a mood stabilizer (HR, 0.99; 95% CI, 0.94-1.04). Initiating use of a mood stabilizer was associated with an increased risk of mortality (HR, 1.31; 95% CI, 1.04-1.66). CONCLUSIONS AND RELEVANCE: In the treatment of schizophrenia, initiating adjunctive treatment with an antidepressant was associated with reduced risk of psychiatric hospitalization and ED visits compared with initiating use of alternative psychotropic medications. Associations of benzodiazepines and mood stabilizers with poorer outcomes warrant clinical caution and further investigation.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Stroup TS, Gerhard T, Crystal S, et al. Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia. JAMA Psychiatry. 2019. PMID: 30785609. doi:10.1001/jamapsychiatry.2018.4489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。